A target-dose finding study of clozapine in patients with schizophrenia. 1996

J A Bennett, and P E Keck
Department of Psychiatry, University of Cincinnati College of Medicine, Ohio, USA.

Evidence from recent studies suggests that clozapine plasma concentrations greater than 350 ng/ml are correlated with therapeutic response. However, little is known about the clozapine dosages required to achieve these plasma concentrations. The purpose of this study was to determine if a target dose of 6 mg/kg/day of clozapine would produce a steady state plasma concentration of > 350 ng/ml. Twelve patients with schizophrenia by DSM-III-R criteria who were refractory to treatment with standard antipsychotics were treated with clozapine utilizing a 10- to 14-day titration to a target dose of 6 mg/kg/day. The mean (+/- SD) clozapine plasma concentration achieved after 5 days at the target dose was 584 +/- 417 ng/ml. Thus, although the target dose successfully produced therapeutic plasma concentrations for most patients, a wide variation was also apparent.

UI MeSH Term Description Entries
D007297 Inpatients Persons admitted to health facilities which provide board and room, for the purpose of observation, care, diagnosis or treatment. Inpatient
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J A Bennett, and P E Keck
December 1998, Journal of clinical psychopharmacology,
J A Bennett, and P E Keck
June 2017, The Cochrane database of systematic reviews,
J A Bennett, and P E Keck
January 2022, Therapeutic advances in psychopharmacology,
J A Bennett, and P E Keck
November 1999, The American journal of psychiatry,
J A Bennett, and P E Keck
July 2012, Proceedings of the National Academy of Sciences of the United States of America,
J A Bennett, and P E Keck
January 2022, American journal of therapeutics,
J A Bennett, and P E Keck
February 2007, Journal of clinical psychopharmacology,
J A Bennett, and P E Keck
November 2000, European journal of clinical pharmacology,
Copied contents to your clipboard!